Raymond James Trust N.A. Increases Position in Becton, Dickinson and Company (NYSE:BDX)


Share on StockTwits

Raymond James Trust N.A. boosted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 3.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,132 shares of the medical instruments supplier’s stock after purchasing an additional 522 shares during the period. Raymond James Trust N.A.’s holdings in Becton, Dickinson and were worth $3,536,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Simon Quick Advisors LLC increased its stake in shares of Becton, Dickinson and by 1,657.1% in the third quarter. Simon Quick Advisors LLC now owns 123 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 116 shares during the period. Dimension Capital Management LLC purchased a new position in shares of Becton, Dickinson and during the third quarter worth approximately $29,000. Sun Life Financial INC purchased a new position in Becton, Dickinson and during the 3rd quarter worth $40,000. Mirova grew its position in Becton, Dickinson and by 428.9% during the 3rd quarter. Mirova now owns 201 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 163 shares during the last quarter. Finally, TFC Financial Management purchased a new position in Becton, Dickinson and during the 3rd quarter worth $53,000. 83.22% of the stock is currently owned by institutional investors.

Shares of NYSE BDX opened at $263.01 on Thursday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.07 and a current ratio of 1.54. Becton, Dickinson and Company has a 1 year low of $197.75 and a 1 year high of $286.72. The stock’s 50-day simple moving average is $245.03 and its 200-day simple moving average is $245.48. The firm has a market cap of $76.50 billion, a price-to-earnings ratio of 96.34, a PEG ratio of 2.27 and a beta of 0.79.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Tuesday, November 10th. The medical instruments supplier reported $2.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.27. The business had revenue of $4.78 billion during the quarter, compared to analyst estimates of $4.48 billion. Becton, Dickinson and had a net margin of 5.11% and a return on equity of 13.30%. The business’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.31 earnings per share. As a group, research analysts predict that Becton, Dickinson and Company will post 12.5 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th were given a $0.83 dividend. The ex-dividend date of this dividend was Wednesday, December 9th. This represents a $3.32 annualized dividend and a dividend yield of 1.26%. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.79. Becton, Dickinson and’s payout ratio is presently 32.55%.

In related news, EVP Roland Goette sold 930 shares of the business’s stock in a transaction dated Monday, November 23rd. The stock was sold at an average price of $230.10, for a total value of $213,993.00. Following the completion of the sale, the executive vice president now directly owns 10,085 shares of the company’s stock, valued at $2,320,558.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.76% of the stock is owned by insiders.

A number of equities analysts recently issued reports on BDX shares. Morgan Stanley raised Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $262.00 to $297.00 in a report on Tuesday, December 15th. TheStreet downgraded Becton, Dickinson and from a “b” rating to a “c+” rating in a research report on Monday, September 21st. Raymond James reduced their price target on Becton, Dickinson and from $285.00 to $270.00 and set an “outperform” rating on the stock in a research note on Monday, October 12th. Zacks Investment Research downgraded Becton, Dickinson and from a “buy” rating to a “hold” rating and set a $276.00 target price on the stock. in a research report on Wednesday. Finally, Wells Fargo & Company lowered shares of Becton, Dickinson and from an “overweight” rating to an “equal weight” rating and set a $265.00 price objective on the stock. in a report on Tuesday, December 15th. Eight equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $280.71.

About Becton, Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: CBOE Russell 2000® Volatility Index

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.